What Adrekar (Adenosine) Treats: Main Uses and Benefits

This medication is applied across domains where additional symptomatic support is needed, primarily for patients experiencing sudden, severe episodes of heart racing, clinically known as Paroxysmal Supraventricular Tachycardia (PSVT). This therapeutic use is relevant for managing symptoms that interfere with daily comfort. The drug is generally used for conditions presenting with acute episodes of types of rapid, symptomatic heart rhythms, including those associated with specific types of electrical disturbances.

A second, distinct application is commonly used across conditions presenting with acute episodes of suspected heart health issues by helping clinicians assess the blood supply to the heart muscle. This involves its use during diagnostic stress testing when the patient is unable to perform adequate physical activity. This process assists with maintaining functional stability by providing a relevant diagnostic assessment.

“The primary benefit of this medication is providing support that helps ease the overall symptom burden during a difficult episode of racing heartbeat.”

Focus: Acute Symptom Management and Cardiac Assessment

Regulatory References

1. NIH StatPearls overview

Eligibility Map: Who can and cannot use Adrekar (Adenosine) — Official Regulatory Information

The eligibility profile for Adrekar (Adenosine) is defined by regulatory bodies through specific prohibitions and conditional-use rules, focusing heavily on pre-existing cardiac and pulmonary conditions.

---

Category	Official Regulatory Statement
Populations for whom use is allowed	Adult Patients for all approved indications. Pediatric Patients for the therapeutic conversion of Paroxysmal Supraventricular Tachycardia (PSVT).
Populations for whom use is contraindicated	Patients with Second- or Third-Degree AV Block or Sick Sinus Syndrome (unless a functional pacemaker is present). Patients with known or suspected Bronchospastic Lung Disease (e.g., asthma). Patients with Known Hypersensitivity to adenosine.
Age-related eligibility rules	Use for diagnostic stress testing is not established in pediatric patients. No specific restriction is noted for use in older adults.
Condition-specific eligibility rules	Use is not restricted by renal or hepatic impairment. Caution is required in patients with First-Degree AV Block or unstable angina.
Pregnancy and lactation eligibility status	Pregnancy: Use is restricted to cases only if clearly needed and the benefit outweighs the potential risk. Lactation: Use is not recommended.

---

Eligibility classifications (high-level)

The medicine is subject to Absolute Contraindications for cardiac conduction disorders and pulmonary disease. Eligibility is otherwise considered Established across adult populations, but is Not Established for the diagnostic use in children, creating a usage-specific limitation.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Adenosine by its functional outcomes on the heart and its cellular clearance pathways. This includes strict requirements for separating the administration of certain substances.

Interaction Scope (Regulatory Classification)	Official Constraint or Description
Nucleoside Transport Inhibitors (e.g., Dipyridamole)	Inhibits Adenosine reuptake; results in potentiation (increased plasma exposure and effect). The combination is formally contraindicated in some regulatory regions, requiring a mandatory 24-hour withholding period prior to administration if its use is unavoidable.
Methylxanthines (e.g., Theophylline, Caffeine)	Acts as a competitive antagonist, diminishing Adenosine's effect and potentially rendering a standard dose ineffective.
Cardioactive Drugs (e.g., Digoxin, Carbamazepine)	Potential for additive or synergistic depressant effects on the SA and AV nodes is noted in official documentation.
Timing-based Separation Rules	Xanthine-containing foods/drinks must be avoided for at least 12 hours (preferably 24 hours) before diagnostic use due to their antagonistic effect.
Population-specific Note	Patients who have undergone recent heart transplantation (less than one year prior) have a documented increased cardiac sensitivity to Adenosine's effects.

Official Interaction Statements

Regulatory documentation defines Adenosine's interaction profile based on two primary functional outcomes: pharmacodynamic antagonism by xanthines, which reduces its effectiveness, and pharmacokinetic potentiation by nucleoside transport inhibitors, which increases its exposure. This structure mandates strict pre-administration timing separation rules for these classes of substances. No clinically relevant cytochrome P450-mediated metabolic interactions are formally documented in regulatory labeling. The profile is limited to interactions directly affecting its cardiac conduction and rapid clearance.

How Adrekar (Adenosine) Works

The mechanism of Adenosine involves acting as an agonist on specific purine receptors ( A1 and A2A) to exert two primary, transient physiological effects: an acute electrical block in the heart and rapid vasodilation.

---

Modulating Electrical Conduction via A1 Receptor Agonism

This domain covers the drug's core antiarrhythmic action by targeting the Adenosine A1 Receptor located in the Atrioventricular (AV) node. Activation of this receptor initiates an inhibitory cascade, causing the opening of potassium channels and inhibition of calcium channels in AV nodal cells . The resulting hyperpolarization of the cell membrane drastically slows the electrical signal transmission and increases the tissue's refractory period, providing a mechanism to acutely terminate electrical re-entry circuits.

---

Acute Regulation of Vascular Tone and Flow

Adenosine also engages the A2A Receptor on vascular smooth muscle, activating a distinct cascade that leads to immediate vasodilation. This mechanism, separate from the electrical effect, results in a rapid, transient reduction in vascular resistance in the coronary and peripheral arteries.

---

Mechanistic Constraint of Rapid Clearance

As an endogenous nucleoside, Adenosine is quickly taken up and metabolized by adenosine deaminase in the bloodstream. This rapid biological clearance ensures that the profound electrical and vascular effects are extremely brief and transient, which is dictated by its inherent short biological half-life.

How to Use Adrekar (Adenosine) — Official Administration Guidelines

Adenosine is a sterile solution for injection that must be administered only in a specialized clinical setting where continuous electrocardiogram (ECG) monitoring and immediate access to resuscitative measures are available. The drug's usage is highly procedural, defined by two distinct administration protocols:

---

Administration Scope

Property	Instruction
Route of administration	Strictly Intravenous (IV) only.
Dosing schedule (PSVT Conversion)	Initial dose of 6 mg rapid IV bolus over 1–2 seconds. If no conversion within 1–2 minutes, a 12 mg rapid IV bolus may be given, repeated once more if needed.
Dosing schedule (Diagnostic Stress)	Continuous peripheral IV infusion at a rate of 0.14 mg/kg/min.
Preparation requirements	The solution must be visually inspected for particulate matter or discoloration prior to use; it must not be administered if either is observed.
Age-group administration rules	Pediatric PSVT Dosing: Initial bolus of 0.05 to 0.1 mg/kg, escalating in increments to a maximum single dose of 0.3 mg/kg or 12 mg.

---

Resulting Procedural Structure

Official step sequence for PSVT Conversion (Rapid Bolus):

• Administer the dose (6 mg or 12 mg) as a rapid intravenous bolus over 1 to 2 seconds into a peripheral vein or IV line as close to the patient as possible.
• Immediately follow the bolus with a rapid saline flush (e.g., 20 mL) to ensure prompt delivery to the central circulation.
• Sequential repeat doses are scheduled for 1 to 2 minutes after the prior dose if required.

Official step sequence for Diagnostic Stress Testing (Infusion):

• Administer the infusion over a fixed duration of 6 minutes via a continuous peripheral intravenous line.
• The diagnostic radiotracer (e.g., Thallium-201) is injected at the midpoint of the 6-minute infusion (i.e., after the first three minutes).

This medication is solely intended for acute, short-term use and is not part of a long-term maintenance regimen. Specific official procedural constraints, such as the required immediate saline flush and fixed infusion timing, are essential due to the drug’s extremely rapid half-life.

Evidence for Use in Acute Heart Rhythm Management

The clinical evidence for the management of specific heart rhythm conditions, such as Paroxysmal Supraventricular Tachycardia (PSVT), consists mainly of Randomized Controlled Trials (RCTs) and Systematic Reviews. Researchers primarily monitored outcomes describing episodic changes, including the rate and measured time interval required for the heart rhythm to return to a normal pattern. Research highlights the specific changes in heart rhythm that were measured shortly after administration. However, because these studies are designed around the immediate event, evidence is limited regarding long-term outcomes following its acute use.

---

Evidence for Use in Diagnostic Cardiac Assessment

This medication was studied for its use in Diagnostic Cardiac Assessment, particularly for Myocardial Perfusion Imaging. The evidence includes Diagnostic Accuracy Studies that evaluated outcomes related to systemic imbalance by monitoring blood flow to the heart muscle. Findings describe patterns where test results were associated with the findings of other detailed diagnostic methods, contributing to the assessment of heart blood flow in a controlled setting. Since this approach is a pharmacological simulation, there is limited information for long-term outcomes regarding functional capacity.

---

Long-Term Studies and Follow-up

For acute heart rhythm management, follow-up durations were limited to the short term, and long-term effects related to this specific use are not fully established. For the diagnostic assessment, observational studies explored whether the initial test result was associated with future clinical events over periods of several years. While these findings help contextualize outcomes, data are still emerging and certainty remains low regarding the sustained, long-term impact on overall patient outcomes.

---

Evidence in Special Populations

Research has explored the use of this medication in special populations, including children, in the context of heart rhythm conditions, with findings describing measured changes in heart rhythm patterns within this group. However, research limitations are notable for other groups. Data for certain populations, such as older adults with complex co-morbid conditions or pregnant patients, remain insufficient, and subgroup findings are uncertain.

---

What is Still Uncertain about Adrekar (Adenosine)

The available research provides context but not individual predictions. There are limitations where certainty remains low, including the variability across study protocols concerning the precise administration techniques and dose levels used. Comparative evidence against all alternative pharmacological options is still being developed. These research limitations mean that findings describe group patterns, not personal outcomes.

Key Studies & References

1. ASNC Practice Points: Pharmacologic Stress Testing – Adenosine
2. Public Assessment Report for paediatric studies submitted in accordance with Regulation (EC) No1901/2006, as amended ADENOSINE
3. Adenosine vs. Regadenoson in Cardiac Stress Testing (ACC Clinical Topic)

Common questions about Adrekar (Adenosine) (FAQ)

---

Q: Are there any long-lasting side effects from receiving Adrekar?

Official regulatory documents indicate that most adverse effects are transient and usually last less than one minute due to the drug’s extremely rapid clearance from the body. However, product information describes a small percentage of reported reactions that were observed to persist for up to 24 hours.

---

Q: Does Adrekar interact with common blood pressure medications?

Regulatory documents state that caution is necessary when the drug is used with other medications that have a depressant effect on the heart's electrical system, such as Digoxin and Verapamil. It is noted that Adrekar itself may cause transient changes in blood pressure, including low blood pressure (hypotension).

---

Q: Does the feeling of chest pressure from Adrekar mean I am having a heart attack?

Chest discomfort or pressure is reported as a very common and usually transient side effect. While the experience is often brief, regulatory documentation also lists serious cardiac events, including Myocardial Infarction (heart attack), as a rare potential risk. Administration of this drug is required to take place in a setting with continuous cardiac monitoring and immediate access to emergency support.

---

Q: Does Adrekar cause headaches that linger after the procedure is over?

Headache is documented as a very common side effect. Although the most profound effects of the medication are extremely short-lived, regulatory reports show that some adverse reactions were observed to persist beyond the typical rapid clearance period, lasting up to 24 hours.

---

Q: Are there any known foods or supplements that interact with Adrekar?

Official product information specifically states that the drug's effect is diminished by methylxanthines, which are found in common substances like caffeine and theophylline. Regulatory documents do not generally detail interactions with common herbal or vitamin supplements.

---

Q: Is the sensation of 'impending doom' or panic a common experience with Adrekar?

Official safety information reports adverse effects related to the central nervous system, including nervousness and apprehension, with an incidence of up to 2% in clinical trials. These reported central nervous system effects may relate to the intense, transient sensation some individuals describe.

---

Q: Is Adrekar used for people with Wolff-Parkinson-White (WPW) syndrome?

The official indication includes the conversion of a fast heart rhythm (PSVT) that is associated with accessory bypass tracts, such as in Wolff-Parkinson-White syndrome. However, the product information requires caution, as the drug can precipitate more dangerous arrhythmias in certain circumstances.

---

Q: Is Adrekar the same drug as the brand name Adenoscan?

Adenosine is the active ingredient. Adenoscan and Adenocard are brand names for the Adenosine injection. According to regulatory references, Adenoscan is often associated with the diagnostic use (stress testing), while Adenocard is often associated with the therapeutic use (rhythm conversion).

---

Q: What is the research evidence for using Adrekar in emergency situations?

The drug is indicated for the acute conversion of Paroxysmal Supraventricular Tachycardia (PSVT), a condition that is frequently treated in acute care and emergency settings. Official product information requires that resuscitative equipment be immediately available at the time of administration.

---

Q: Does Adrekar affect the function of a pre-existing pacemaker?

The drug is contraindicated (prohibited) in patients with certain high-grade heart block conditions unless a functioning artificial pacemaker is present. The pacemaker's presence overrides the contraindication, indicating it allows for the safe administration of the drug in these specific cases.

---

Q: Is a metallic taste in the mouth or a stiff feeling in the neck a reported side effect?

Yes. Regulatory safety labeling lists throat, neck, or jaw discomfort as a very common adverse reaction. Metallic taste is also listed in official reports as a less common side effect.

---

Q: Can Adrekar cause confusion or temporary memory issues, as some patients describe?

The regulatory safety labeling lists confusion as a less common side effect. Other central nervous system effects reported in official documents include drowsiness and, rarely, seizure activity.

How to Store and Dispose of Adrekar (Adenosine)

Adrekar (Adenosine) Injection must be stored at controlled room temperature, typically 20^circ to 25 C (68^circ to 77 F). A critical requirement is do not refrigerate the product, as this can cause the active ingredient to crystallize. Should crystallization occur, the solution must be warmed to room temperature until it is clear and colorless before use.

Key Storage and Disposal Rules

Domain	Official Requirement
Temperature	Store at controlled room temperature; Do not refrigerate
Stability	For immediate use once opened; discard any unused portion
Safety	Keep out of the sight and reach of children
Disposal	Dispose of according to local requirements; do not use household waste or wastewater

The solution must be visually inspected for particles or discoloration prior to administration. Disposal of the unused product and related waste must strictly follow local pharmaceutical waste protocols.